PEDIATRIC SURGERY *Update**
Volume 66 No. 06 JUNE 2026

Neurodivergent Conditions

Neurodiversity refers to the natural variation in how human brains process and interpret information and produce behavioral responses. Rather than framing these differences as deficits to be corrected, the neurodiversity paradigm — a concept that has gained considerable traction in both clinical and social discourse since its coining in the late twentieth century — repositions them as part of the ordinary spectrum of human variation. Approximately 15 to 20 percent of the global population is estimated to carry a neurodivergent condition of some kind, encompassing conditions such as autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), dyslexia, dyscalculia, dysgraphia, and Tourette syndrome. In the United States alone, current estimates suggest that roughly one in every 31 children receives an ASD diagnosis by age eight. Despite the prevalence of these conditions, tailored, inclusive clinical approaches remain far from universal — a gap whose consequences are felt at every level of healthcare and daily life.

Understanding neurodivergent conditions requires moving away from the assumption that they can be cleanly separated into discrete diagnostic categories. The phenotypic boundaries between conditions are frequently blurred, with co-occurrence being the rule rather than the exception. Roughly 30 to 50 percent of children with ASD also display signs of ADHD, typically emerging around preschool age. The conditions share overlapping traits — social communication difficulties, sensory processing differences, challenges with executive functioning — while differing in the specific configurations and severities of those traits. This phenotypic overlap has important consequences for research and clinical care alike. Historically, investigations into neurodevelopmental conditions have been conducted within diagnostic silos, studying autism separately from ADHD, ADHD separately from obsessive-compulsive disorder, and so on. The evidence base produced by this approach reflects its limitations: findings that emerge from any one diagnostic group may or may not generalize to others, and the shared mechanisms that underlie multiple conditions remain poorly understood.

A growing body of recent work has begun to address this gap through what is termed a transdiagnostic perspective — one that examines traits and outcomes across conditions rather than within them. A striking illustration comes from research into theory of mind (ToM), the capacity to understand that other people hold their own mental states, beliefs, and intentions. ToM is fundamental to social interaction, and difficulties with it have been closely associated with autism. For decades, impaired ToM has been treated almost as a defining feature of autistic cognition. Yet when the same capacities are examined across

children with autism, ADHD, and OCD together, a more nuanced picture emerges. While children with autism do show more difficulty than their peers on certain ToM tasks — specifically in the pertinence and coherence of the social narratives they produce — the diagnostic category itself turns out to be a weaker predictor of ToM performance than phenotypic variables such as IQ and social communication difficulties. In other words, knowing that a child has autism tells you less about their ToM abilities than knowing their verbal IQ and the severity of their social communication challenges. These phenotypic variables cut across diagnostic boundaries, predicting performance similarly in children with ADHD, OCD, and neurotypical development. The implication is significant: interventions and assessments built around ToM — and by extension, social cognition more broadly — may need to be calibrated to a child's functional profile rather than their diagnostic label.

Similar conclusions emerge when examining health-related quality of life (HRQoL) across neurodivergent populations. HRQoL is a multidimensional construct that spans biological, symptomatic, functional, and environmental domains, and it is one of the most clinically meaningful outcomes in pediatric care. Systematic analysis of the available evidence reveals that the predictors of quality of life in neurodivergent children are not diagnosis-specific. Positive associations with HRQoL have been observed for adaptive functioning, positive self-perception, physical activity, available resources, and a supportive family context — and these associations appear consistently across conditions, not uniquely within any one of them. Negative associations, meanwhile, emerge reliably from elevated diagnostic symptom burden and comorbid mental health difficulties. The research landscape on HRQoL in neurodivergent children remains skewed, with the vast majority of available studies focused on autism and ADHD and very little attention paid to conditions such as intellectual disability, communication disorders, or tic disorders. Even within the studies that do exist, cross-diagnosis comparisons are rare. This means that care models are being built on an incomplete map, often assuming that what helps a child with ADHD will not necessarily apply to one with autism, when the evidence increasingly suggests that shared needs and shared predictors deserve a shared response.

The transdiagnostic reality of neurodivergent conditions becomes especially visible — and especially consequential — in healthcare settings, where the clinical environment itself can become a source of distress. Children with neurodivergent conditions require medical and surgical procedures at rates comparable to or higher than their neurotypical peers, and in some cases higher still: many routine procedures that neurotypical children tolerate with standard preparation — blood draws, dental cleanings, imaging — require sedation or more elaborate planning for neurodivergent children because of heightened sensory sensitivities, difficulty tolerating uncertainty, and challenges with communication. The perioperative environment is particularly demanding. It combines multiple potential stressors simultaneously: unfamiliar lights, sounds, and smells; physical contact with strangers; unfamiliar clothing and monitoring equipment; prolonged waiting; separation from caregivers; and the prospect of pain. For a child with sensory processing differences, any

one of these might be overwhelming; their combination can provoke acute dysregulation that looks, to an unprepared clinician, like non-compliance rather than distress.

Evidence-based strategies for managing procedural distress in children exist, but they have been developed primarily for neurotypical populations. Their applicability to neurodivergent children has been poorly studied, and current research reveals significant gaps in coverage. Reviews of the literature on procedural support for neurodivergent children show that the overwhelming majority of available evidence — as much as 84 percent of included studies — focuses specifically on autism spectrum disorder, leaving children with ADHD, intellectual disabilities, learning disorders, communication disorders, and other neurodivergent profiles with almost no dedicated evidence base to guide their care. The support strategies most commonly studied — visit preparation, pharmacological agents, and individualized care plans — show promise, but their evaluation is hampered by inconsistent outcome measurement. Fewer than five percent of studies include child-reported pain measures; most distress outcomes are recorded through behavioral observation rather than validated instruments. This means that the child's own experience of the procedure — their perception of pain, their subjective sense of safety or threat — is largely absent from the evidence.

What emerges from the research that does exist is a consistent emphasis on individualization. No single protocol for managing procedural distress can be applied uniformly across neurodivergent children, because the relevant variables — sensory sensitivities, communication preferences, anxiety triggers, past healthcare experiences, and coping strategies — vary not only between conditions but within them. The principle "if you've met one individual with autism, you've met one individual with autism" captures something that applies equally well to the full range of neurodivergent conditions: phenotypic heterogeneity is the defining feature, and standardized approaches fail to honor it. The most effective perioperative interventions identified in available research involve individualized care plans developed in advance through collaboration with the child and their caregivers. These plans document the child's specific sensory profile, communication methods, behavioral triggers, and any accommodations — environmental modifications, preferred distraction strategies, altered routes of medication administration — that have been effective in previous encounters. When implemented consistently and shared across the care team, such plans have been associated with improvements in caregiver-reported satisfaction, perceived safety, and the child's capacity to manage stress during procedures.

The family context, and particularly the role of primary caregivers, is an understated dimension of neurodivergent care that recent work has begun to illuminate. Caring for a neurodivergent child involves a volume of invisible labor — seeking, evaluating, and acting on health information — that is rarely acknowledged in clinical models. Interviews with mothers of neurodivergent children reveal that this information work is not merely cognitive but deeply emotional. Navigating fragmented care systems, advocating for recognition of contested diagnoses, and managing the emotional responses of teachers, clinicians, and

other family members while simultaneously suppressing their own requires sustained effort. Diagnoses associated with neurodivergent conditions are frequently contested — their validity questioned, their severity underestimated, their implications disputed — and this contestation intensifies the emotional burden on caregivers who must simultaneously manage their own feelings and perform appropriate affect for the systems they are negotiating with. The weight of this work falls disproportionately on mothers, reflecting broader social structures in which primary caregiving responsibilities remain gendered. Recognizing this dimension of the caregiving experience matters for clinical practice: the parent or guardian accompanying a neurodivergent child to a medical appointment is not only an informant but a partner who has likely already invested enormous effort in preparing that child for the encounter.

The picture that emerges from the current literature is one of a population that is both larger and more diverse than clinical practice often acknowledges, and whose needs are more shared across diagnostic categories than siloed research traditions would suggest. Neurodivergent conditions collectively affect a substantial proportion of children, presenting with overlapping phenotypes, shared quality-of-life predictors, and common vulnerabilities in healthcare environments. The shift toward transdiagnostic frameworks — in research design, in clinical assessment, and in care delivery — is not merely an academic preference but a practical necessity. Understanding that social cognitive difficulties, sensory sensitivities, and family burden do not respect diagnostic boundaries is the first step toward building systems of care that do not, either.

References:

1- Laurin E, Andersson L: Emotion work and emotional labour, neglected facets of parental health information work. Analysing mothers of neurodivergent children. Sociol Health Illn. 46(5):1023-1053, 2024

2- Mahjoob M, Paul T, Carbone J, Bokadia H, Cardy RE, Kassam S, Anagnostou E, Andrade BF, Penner M, Kushki A: Predictors of Health-Related Quality of Life in Neurodivergent Children: A Systematic Review. Clin Child Fam Psychol Rev. 27(1):91-129, 2024

3- Veeravalli S, Michaud M, Colton J, Bourdeau B, Sacks S, Hales L, Guadagno E, Poenaru D: Adapting Perioperative Care for Neurodivergent Children - A Scoping Review. J Pediatr Surg. 60(5):162224, 2025

4- Amorim K, Vandewouw MM, Huynh N, de Villa K, Safati C, Almonte A, Nicolson R, Kelley E, Crosbie J, Brian J, Anagnostou E, Taylor MJ, Sato J: A transdiagnostic study of theory of mind in children and youth with neurodevelopmental conditions. Mol Autism. 16(1):37, 2025

5- Nchinda N, Cabral KP, Frigon C, Colton J, Henry M: Lessons in patient-centered care and perioperative practices for children with neurodivergent conditions. J Pediatr Surg. 61(3):162689, 2026

6- Takashima M, Robertson H, Plummer K, Kotzur C, Wesley A, Donaldson A, Hjelmgren H, Stålberg A, Burgess L, Friedman AJ, Mimmo L, Choi J, Barker N, Gooley S, Walsh N, Cobham VE, Ullman A: Procedural Support for Neurodivergent Children During Medical Procedures: A Scoping Review. Clin Child Fam Psychol Rev. 29(1):167-181, 2026

3-D Printing in Pediatric Surgery

Technological progress has repeatedly reshaped surgical practice, from the development of modern imaging techniques to the emergence of minimally invasive procedures. Among the newest innovations influencing pediatric surgical care is three-dimensional (3-D) printing,

also known as additive manufacturing. This technology enables the transformation of digital imaging data into tangible physical models that replicate patient-specific anatomy. Over the past decade, 3-D printing has moved from experimental prototypes to increasingly practical tools in clinical medicine. In pediatric surgery, where anatomical complexity and variability are common, this technology offers unique opportunities to improve surgical planning, education, and patient communication.

The fundamental concept of 3-D printing is relatively straightforward. Imaging studies such as computed tomography or magnetic resonance imaging generate digital datasets that can be processed into three-dimensional reconstructions. Specialized software is used to segment anatomical structures from these images and convert them into digital models. Once created, these models can be exported into printable formats and manufactured layer by layer using materials such as thermoplastics, resins, or other polymers. The resulting objects provide a physical representation of the patient's anatomy, often at a one-to-one scale, allowing surgeons to directly visualize relationships between organs, vessels, and pathological structures.

The application of 3-D printing in pediatric surgery is particularly appealing because pediatric patients frequently present with congenital anomalies or complex anatomical variations. Standard two-dimensional imaging, while highly informative, can sometimes be difficult to interpret in cases involving distorted anatomy or unusual spatial relationships. Three-dimensional reconstructions help bridge this gap by providing a more intuitive representation of anatomical structures. When these reconstructions are converted into physical models, the surgeon can examine the anatomy from multiple perspectives, gaining insights that may not be easily appreciated on conventional imaging studies.

Preoperative planning represents one of the most widely recognized uses of 3-D printing in pediatric surgical practice. Complex operations often require careful evaluation of the spatial relationship between lesions and surrounding structures such as major vessels or adjacent organs. Physical models derived from patient imaging can provide an enhanced understanding of these relationships. Surgeons may manipulate the model, simulate different operative approaches, and anticipate technical challenges before entering the operating room. Such preparation may reduce uncertainty during surgery and potentially improve operative efficiency.

Three-dimensional models have been particularly helpful in cases involving pediatric tumors. Tumors in the retroperitoneum or other anatomically complex regions can involve or displace major vascular structures, making surgical planning difficult. By producing physical models from preoperative imaging, surgeons can better appreciate how the tumor interacts with surrounding anatomy. This approach has demonstrated value in identifying critical structures and facilitating safe tumor resection. Furthermore, models may reveal relationships that were not fully apparent on conventional imaging, allowing surgeons to refine their operative strategy.

Another advantage of three-dimensional printing is its capacity to support personalized

medicine. Pediatric patients vary widely in size, anatomy, and developmental stage. Unlike standardized surgical tools or generic anatomical diagrams, 3-D printed models reflect the individual anatomy of a specific patient. This individualized representation can help surgeons tailor their operative approach and improve decision-making. Personalized anatomical models are particularly useful in fields such as pediatric surgical oncology, where tumors may distort normal anatomy and create unpredictable surgical challenges.

Beyond surgical planning, three-dimensional printing has proven valuable as an educational tool. Surgical trainees often struggle to understand complex anatomical relationships using two-dimensional imaging alone. Physical models provide a tactile learning experience that can improve spatial comprehension and enhance anatomical understanding. Trainees can study the models, explore different operative approaches, and gain familiarity with the surgical anatomy before encountering similar cases in the operating room.

Simulation represents another important educational application. Traditional surgical training relied heavily on the apprenticeship model, in which trainees gradually learned skills through observation and supervised practice. However, ethical considerations and patient safety concerns have encouraged the development of simulation-based training. Three-dimensional printing enables the creation of realistic surgical simulators derived from actual patient anatomy. These simulators allow trainees to practice procedures repeatedly in a controlled environment. In pediatric surgery, where certain procedures are relatively rare, simulation offers a valuable opportunity to develop technical proficiency before performing operations on patients.

The benefits of simulation are particularly evident in procedures that require advanced minimally invasive techniques. Neonatal thoracoscopic operations, for example, involve extremely small operative spaces and delicate tissues. These procedures demand exceptional technical precision and can present a steep learning curve for young surgeons. Realistic simulators produced through 3-D printing can replicate the surgical environment and allow trainees to rehearse complex maneuvers. Such training may reduce intraoperative errors and improve overall surgical performance.

Three-dimensional printing also enhances communication between surgeons and patients' families. Parents often find it difficult to understand surgical conditions when explanations rely solely on medical terminology or two-dimensional images. Physical models of the child's anatomy provide a powerful visual aid that helps families comprehend the nature of the disease and the planned surgical procedure. When parents can see and touch a representation of the anatomical structures involved, their understanding of the condition often improves significantly. This improved communication can facilitate informed consent and strengthen trust between the surgical team and the patient's family.

Despite these promising applications, several challenges remain before 3-D printing becomes a routine component of pediatric surgical care. One of the primary obstacles is cost. The equipment required for high-resolution printing and the materials used to produce

anatomical models can be expensive. In addition, specialized software and trained personnel are necessary to convert imaging data into printable models. For many institutions, these costs represent a significant barrier to widespread adoption.

Another challenge involves the technical complexity of model creation. Producing an accurate anatomical model requires careful segmentation of imaging data. Structures must be identified and separated from surrounding tissues, a process that can be time-consuming when performed manually. Advances in artificial intelligence and automated segmentation algorithms have begun to simplify this process, but the technology is still evolving. Improvements in software tools will likely play an important role in expanding access to 3-D printing technology in clinical practice.

Material limitations also represent an important consideration. Different anatomical structures possess unique mechanical properties that may be difficult to replicate with currently available printing materials. For example, bone, cartilage, and soft tissue differ significantly in texture and elasticity. While modern printing materials can approximate some of these characteristics, achieving realistic tactile properties remains challenging. Continued development of biomimetic materials will be essential for improving the realism of printed models and surgical simulators.

Regulatory and logistical considerations may also influence the integration of 3-D printing into routine clinical workflows. The production of patient-specific devices or implants requires careful attention to safety standards and regulatory guidelines. While most current applications involve anatomical models rather than implantable devices, the regulatory environment will become increasingly important as the technology evolves.

Despite these challenges, the future of 3-D printing in pediatric surgery appears promising. Advances in imaging technology, computing power, and printing materials continue to expand the capabilities of additive manufacturing. Emerging technologies such as virtual reality, augmented reality, and mixed reality are also being integrated with 3-D modeling platforms, creating new possibilities for surgical visualization and planning. These tools allow surgeons to interact with digital anatomical models in immersive environments, further enhancing spatial understanding of complex anatomy.

Artificial intelligence may further accelerate the development of this field. Automated image segmentation and machine learning algorithms can rapidly identify anatomical structures within imaging datasets, significantly reducing the time required to generate three-dimensional models. As these tools become more sophisticated, the creation of patient-specific models may become faster and more accessible, enabling broader clinical adoption.

In the long term, the integration of 3-D printing with other emerging technologies may lead to even more transformative applications. Patient-specific implants, customized surgical instruments, and bioengineered tissues represent potential future directions. Although many of these innovations remain in early stages of development, they illustrate the

potential of additive manufacturing to fundamentally reshape surgical care.

In summary, three-dimensional printing has emerged as a valuable technological innovation in pediatric surgery. By converting imaging data into physical models, this technology provides surgeons with a powerful tool for visualizing complex anatomy, planning operations, and improving surgical education. Applications extend beyond operative planning to include simulation training and enhanced communication with patients and families. While challenges related to cost, technical complexity, and material limitations remain, ongoing technological advances are likely to expand the role of 3-D printing in pediatric surgical practice. As these innovations continue to evolve, additive manufacturing may become an increasingly important component of personalized pediatric surgical care.

References:

1- Hong D, Kim H, Kim T, Kim YH, Kim N: Development of patient specific, realistic, and reusable video assisted thoracoscopic surgery simulator using 3D printing and pediatric computed tomography images. Sci Rep. 11(1):6191, 2021

2- Valls-Esteve A, Adell-Gómez N, Pasten A, Barber I, Munuera J, Krauel L: Exploring the potential of three-dimensional imaging, printing, and modeling in pediatric surgical oncology: a new era of precision surgery. Children (Basel). 10(5):832, 2023

3- Youn JK, Park SJ, Choi YH, Han JW, Ko D, Byun J, Yang HB, Kim HY: Application of 3D printing technology for pre-operative evaluation, education and informed consent in pediatric retroperitoneal tumors. Sci Rep. 13(1):1671, 2023

4- Tsai AY, Greene AC: 3D printing in pediatric surgery. Semin Pediatr Surg. 33(1):151385, 2024

5- Ryan ML, Knod JL, Pandya SR: Creation of three-dimensional anatomic models in pediatric surgical patients using cross-sectional imaging: a demonstration of low-cost methods and applications. J Pediatr Surg. 59(3):426-431, 2024

6- Youn JK, Ko D, Yang HB, Kim HY: A 3D printed esophageal atresia-tracheoesophageal fistula thoracoscopy simulator for young surgeons. Sci Rep. 14(1):11489, 2024

Neonatal Limb Ischemia

Acute limb ischemia (ALI) in the neonate is defined as a sudden and critical reduction in arterial perfusion to an extremity, sufficient to threaten the viability of muscle and nerve tissue. The window for reversible injury is narrow — generally estimated at four to six hours from onset — after which irreversible ischemic damage to muscle and nerve fibers may ensue. Although the condition is uncommon in the neonatal population, its consequences when unrecognized or inadequately treated include limb loss, growth disturbance, and long-term functional impairment. Reported incidence in neonatal intensive care unit admissions is approximately 2.4 per 1,000, with the vast majority of cases attributable to vascular access procedures. Despite this, no universally accepted, evidence-based guidelines exist for the pediatric and neonatal population. Management continues to rely on expert consensus, extrapolation from adult data, and an expanding but still limited body of case reports and retrospective series.

The causes of neonatal ALI are broadly classified into prenatal and postnatal categories, each with distinct mechanisms and risk profiles.

Prenatal etiologies include intrauterine compression of a major limb artery by an extrinsic process — a phenomenon historically associated with oligohydramnios and amniotic band disruption and known as Volkmann's ischemia — as well as prenatal arterial thrombosis and embolism. Fetal thrombosis is facilitated by the physiological hypofibrinolytic state characteristic of the neonatal period, which reflects reduced plasma activity of protein C, protein S, antithrombin III, and plasminogen. This coagulation imbalance, inherent to normal fetal hemostasis, is compounded by clinical risk factors including dehydration, sepsis, polycythemia, congenital heart disease, and inherited thrombophilia. Maternal factors — including pre-eclampsia, diabetes mellitus, prothrombotic conditions, and cocaine use — as well as intrapartum events such as chorioamnionitis, prolonged rupture of membranes, and umbilical cord abnormalities, further amplify fetal thrombotic risk. Prenatal embolism may originate from maternal or placental sources; placental pathologies including infarction, fetal thrombotic vasculopathy, chorioamnionitis, and chorioangiomas have all been implicated in embolic transmission to the fetal arterial circulation.

Postnatal ALI is overwhelmingly iatrogenic. Arterial catheterization — whether umbilical, femoral, radial, brachial, or posterior tibial — accounts for approximately 89% of thrombotic events in neonates, with the femoral artery representing the most frequently affected vessel in institutional series. Thrombosis typically originates at the catheter insertion site, where endothelial disruption initiates platelet aggregation and clot formation. Additional catheter-related risk factors include large catheter diameter relative to vessel size, malposition, prolonged indwelling time beyond six days, rapid intravascular volume shifts, and concurrent use of vasopressors or parenteral nutrition with lipid emulsions. Non-iatrogenic postnatal causes — including spontaneous arterial thrombosis, paradoxical embolism through a patent foramen ovale in the setting of congenital heart disease, and arteriovenous or structural vascular malformations — are rare but must not be overlooked.

At the tissue level, the morphological consequences of ALI evolve with time and etiology. Acute arterial thrombi are characterized histologically by fibrin-platelet aggregates with entrapped erythrocytes. As the thrombus matures, it acquires a more organized architecture incorporating smooth muscle cells, inflammatory cells, and collagen. In catheter-related thrombosis, early lesions show fine fibrin-platelet deposits adjacent to areas of endothelial abrasion; with prolonged catheterization, progressive intimal thickening and medial smooth muscle proliferation occur. Arteriovenous malformations, though rarely biopsied, demonstrate tortuous thick-walled arterial channels with disrupted elastic laminae and arterialized veins resulting from high-pressure flow.

The clinical recognition of ALI in a neonate requires vigilance, as the presenting signs — pallor, cyanotic discoloration, coolness to touch, diminished capillary refill, and absent or weakened distal pulses — may be subtle in the early phases and can evolve rapidly to frank necrosis, bullae formation, and limb demarcation. An absence of Doppler signals at the ankle level is found in approximately two-thirds of affected infants at presentation, and visible cyanosis in roughly sixty percent. Pain responses may be difficult to assess in this population, adding to diagnostic complexity.

Duplex ultrasonography is the cornerstone of diagnostic imaging for neonatal ALI. It is non-invasive, rapidly executable at bedside, and provides sufficient spatial resolution to identify thrombotic occlusion, quantify stenosis, and characterize collateral flow — information that directly informs therapeutic decision-making. More advanced vascular imaging modalities, including computed tomography angiography, magnetic resonance angiography, and digital subtraction angiography, are available but infrequently required and carry additional risks in this fragile population. Serum creatine phosphokinase may serve as a surrogate marker of muscle ischemia severity; markedly elevated levels signal significant tissue compromise and warrant close monitoring for renal impairment through ischemic rhabdomyolysis.

When prenatal ALI is suspected, placental pathological examination — if the placenta has been retained — can provide critical diagnostic information about thrombo-inflammatory processes, maternal circulation derangements, and fetal thrombotic vasculopathy.

The management of neonatal ALI has converged toward a conservative-first approach, supported by growing institutional experience demonstrating that surgical revascularization carries prohibitive risks in this population. Historical data indicate that fewer than half of infants under thirty months who underwent surgical revascularization regained pulses immediately postoperatively, with perioperative mortality reaching twenty-five percent. In contrast, nonoperative management with anticoagulation alone has achieved limb salvage rates approaching ninety-six percent in contemporary series, with no instances of claudication on long-term follow-up in most cohorts.

The initial non-pharmacological response to suspected ALI begins with immediate removal of the offending catheter, elevation of the affected extremity to reduce venous pooling and facilitate gravitational venous return, and application of warm compresses to the contralateral limb to promote reflex vasodilation. These measures, while not sufficient in isolation to reverse established ischemia, are universally recommended and should be implemented without delay.

Anticoagulation with unfractionated heparin (UFH) is the pharmacological cornerstone of first-line therapy. Standard dosing guidelines recommend an intravenous loading dose of 75 units per kilogram of body weight over ten minutes, followed by a continuous maintenance infusion of 28 units per kilogram per hour for infants under one year, with subsequent dose adjustment targeting an activated partial thromboplastin time of 60 to 85 seconds. Because antithrombin III — the primary substrate for UFH — is physiologically reduced in neonates, supplementation with fresh frozen plasma should be considered when antithrombin levels are significantly depressed, as inadequate substrate availability may blunt the anticoagulant response. Transition to low-molecular-weight heparin (LMWH), typically enoxaparin, is preferred as soon as clinically feasible, as subcutaneous dosing is more practical and carries a more predictable pharmacokinetic profile; anti-factor Xa levels provide the appropriate monitoring parameter. The duration of anticoagulation is generally three to twelve weeks, guided by serial duplex ultrasonographic documentation of thrombus resolution.

Topical nitroglycerin (NG) has emerged as an important adjunct in the management of neonatal ALI, particularly in the setting of vasospasm or small-vessel distal ischemia. Nitroglycerin acts as a nitric oxide donor, promoting smooth muscle relaxation and vasodilation through activation of guanylate cyclase and elevation of cyclic guanosine monophosphate. It has been shown to promote collateral circulation at the periphery of ischemic lesions and possesses modest analgesic properties. Its topical application — available as ointment, transdermal patch, or spray — allows for local action with limited systemic absorption, though the ointment formulation appears to carry a more favorable safety profile in neonates than transdermal patches. Reported adverse effects include methemoglobinemia and hypotension, though these are uncommon at standard doses; premature neonates carry a somewhat higher risk due to increased skin permeability. In institutional series spanning four-year observation periods, no significant methemoglobinemia or hemodynamic instability was documented with NG ointment use, and the majority of treated patients achieved at least partial recovery. The optimal dosing, application site, and treatment duration remain heterogeneous across the literature, and no consensus guidelines currently exist. Available evidence supports initiating NG early — ideally at the onset of ALI — as treatment effects are attenuated once necrosis is established.

Thrombolysis with tissue plasminogen activator (tPA) represents the next escalation in the therapeutic algorithm when anticoagulation alone fails to reverse ischemic progression within 24 to 48 hours, or when there is documented propagation of thrombus burden during therapeutic anticoagulation. Dosing in the neonatal population ranges widely, from 0.01 to 0.6 mg per kilogram per hour, administered over variable durations depending on clinical response. Fibrinogen levels, hematocrit, and distal Doppler signals should be monitored at regular intervals during infusion. The major risk of thrombolytic therapy is hemorrhage, and absolute contraindications include thrombocytopenia, recent surgery, and elevated risk of intracranial bleeding — all of which are common in critically ill neonates, particularly those who are premature. For this reason, thrombolysis must be individualized and undertaken only after careful multidisciplinary risk-benefit analysis.

Peripheral nerve block using local anesthetics — most commonly ropivacaine — represents a distinct and underutilized therapeutic pathway that achieves vasodilation through sympathetic blockade rather than pharmacological anticoagulation or thrombolysis. It is particularly relevant when hemorrhagic risk precludes anticoagulation or thrombolysis. Case experience suggests that axillary brachial plexus nerve block, when performed by an experienced pediatric anesthesiologist under ultrasound guidance, can produce marked and rapid improvement in limb perfusion, with effects that are temporally reproducible across repeated procedures. The mechanism involves inhibition of catecholamine-mediated vasoconstriction, promoting vasodilation of peripheral arterial beds downstream from the block site.

Surgical intervention — including microsurgical thrombectomy, embolectomy, or arterial reconstruction — is reserved for limbs in immediate jeopardy of irreversible tissue loss after exhaustion of conservative options, or when there are absolute contraindications to

pharmacological management. When amputation becomes necessary, it should be delayed until necrosis is clearly demarcated, as the extent of ultimately irreversible tissue loss is frequently less than initial clinical appearance suggests; this delay also permits planning for future prosthetic fitting.

Compared with adult ALI, neonatal and infant ALI carries substantially lower rates of amputation and mortality. Amputation rates below two percent and mortality below four percent have been reported in pediatric series, though mortality in the neonatal subgroup is disproportionately higher and often reflects the severity of underlying comorbidities rather than the limb ischemia itself. Deaths in institutional series are consistently attributed to multiorgan failure from sepsis or underlying cardiac disease, not to the vascular event.

Long-term morbidity following successful limb salvage includes limb length discrepancy, chronic wound complications, and rarely claudication. Collateral circulation in young infants appears to develop robustly following acute arterial occlusion, likely reflecting the plasticity of the developing vascular bed and the capacity for rapid neovascularization. Recanalization of occluded arteries, confirmed on serial duplex imaging, occurs in the majority of conservatively managed patients within weeks of diagnosis. Serial Doppler assessment at four-week intervals guides the duration of anticoagulation and documents the adequacy of reperfusion.

The risk of limb length discrepancy resulting from growth plate ischemia has historically been cited as an argument against conservative management, but contemporary data suggest that this complication occurs in a small minority of conservatively managed patients — in the range of four to five percent — which compares favorably with rates of ten to twenty percent reported following surgical revascularization. All patients should receive long-term orthopedic follow-up and neurodevelopmental assessment when the affected limb involves a dominant upper extremity.

The evidence base for neonatal ALI management remains constrained by the rarity of the condition, the ethical limitations on conducting randomized trials in critically ill neonates, and the significant heterogeneity in patient characteristics, etiology, catheter type, and clinical severity across published series. The overwhelming majority of available evidence derives from case reports, small retrospective reviews, and systematic reviews of those reports — a methodological pyramid that limits the generalizability and precision of any individual finding.

Outcome measurement is similarly inconsistent. Most published series define success in terms of gross limb preservation or caregiver-reported functional status, while child-reported pain assessment and validated functional outcome instruments are virtually absent from the literature. This renders meaningful comparison across series difficult and obscures the true burden of long-term morbidity.

What is unambiguous is that neonatal ALI demands immediate recognition, multidisciplinary engagement, and a management philosophy that prioritizes individualization over protocol rigidity. The optimal approach assembles a treatment team

that includes neonatology, vascular surgery, hematology, pharmacy, and — when available — pediatric anesthesiology, and constructs a dynamic management plan that escalates or deescalates therapeutic intensity in response to objective clinical and imaging endpoints. Antithrombin levels should be assessed before initiating heparin. Topical nitroglycerin should be available without delay in any unit where arterial catheterization is performed. Amputation, when unavoidable, should be timed to maximize residual limb length and functional prosthetic potential.

The development of multicenter registries and prospectively defined outcome frameworks represents the most viable path toward evidence-based guidelines for this population. Until such guidelines exist, the current literature supports a conservative-first, individualized, and multidisciplinary approach as the standard of care for neonatal acute limb ischemia.

Neonatal acute limb ischemia is a rare but serious vascular emergency whose management continues to evolve in the absence of randomized controlled evidence. Its etiology is predominantly iatrogenic, rooted in the demands of critical care monitoring in a physiologically vulnerable population. The neonatal coagulation system, vascular caliber, and capacity for collateralization are fundamentally different from the adult, rendering downward extrapolation of adult treatment algorithms both inadequate and potentially harmful. Conservative management with anticoagulation and topical nitroglycerin, supported by judicious use of thrombolysis and nerve block, has demonstrated favorable limb salvage rates with acceptable long-term functional outcomes. Surgical revascularization carries high procedural risk in this age group and should be reserved for situations where pharmacological approaches have failed, and limb viability is immediately threatened. Standardized treatment protocols, supported by prospective multicenter data, remain an unmet need in the care of this fragile population.

References

1- Cerbu S, Bîrsăşteanu F, Heredea ER, Iacob D, Iacob ER, Stănciulescu MC, Boia ES. Acute limb ischemia in neonates: etiology and morphological findings — short literature review. Rom J Morphol Embryol. 59(4):1041–1044, 2018

2- Wang SK, Lemmon GW, Drucker NA, Motaganahalli RL, Dalsing MC, Gutwein AR, Gray BW, Murphy MP. Results of nonoperative management of acute limb ischemia in infants. J Vasc Surg. 67(5):1480–1483, 2018

3- Slee SL, Ma Y. Management of neonatal limb ischemia secondary to peripheral arterial lines: a systematic review. J Pediatr Intensive Care. 13:315–320, 2024

4- Bsat A, Lawandos L, Nabhani S, Hafez B, Haddad F. Challenges in treating neonatal acute limb ischemia: conservative management with successful limb salvage. Case Rep Vasc Med. 2025:2424543, 2025

5- Jesus AR, Fradique AR, Teixeira C, Carvalho L, Dionísio T. Use of topical nitroglycerin in the treatment of acute limb ischemia: four-year experience in a mixed neonatal and pediatric intensive care unit. J Mother Child. 30(1):49–57, 2026

6- Shaniv D, Simpson-Lavy Y, Hershkovich Shporen C. Management of iatrogenic acute limb ischaemia in the neonate. BMJ Case Rep. 17:e261775, 2024

***Edited by: Humberto Lugo-Vicente, MD, FACS, FAAP**
Professor of Pediatric Surgery, UPR - School of Medicine, UCC School of Medicine & Ponce School of Medicine.
Pediatric Surgery, San Jorge Hospital.
Postal Address: P.O. Box 10426, San Juan, Puerto Rico USA 00922-0426.
Tel (787) 340-1868 E-mail: *pediatricsurgerypr@gmail.net*
Internet: pedsurgeryupdate.com

ISSN 1089-7739